Obesity Drug News Today: Latest GLP-1 Medications Compared

The obesity drug race just got faster. New trial data from Eli Lilly and Novo Nordisk is reshaping what patients and investors can expect from the latest weight loss medications. This article cuts through the noise with concrete comparisons, safety facts you need to know, and what’s actually coming next.

Obesity drug share of pharma R&D returns: 25% ·
Patients on Wegovy pill (U.S.): >1 million ·
Survodutide weight loss vs Zepbound: 16% more ·
Novo Nordisk Q1 2026 profit: Beat forecasts

Here are four data points that capture the current state of the obesity drug market.

What is the new drug for obesity?

The most recent addition to the obesity drug arsenal making headlines is survodutide, a GLP-1/GIP/glucagon triple agonist developed by Eli Lilly. In phase 3 trial results published in May 2026, survodutide led to 16% more weight loss compared to Zepbound (tirzepatide), according to Healthline (medical news). Meanwhile, Novo Nordisk’s oral Wegovy pill has surpassed 1 million U.S. patients, the company reported in its Q1 2026 earnings call (RTE (news)).

When will retatrutide be available?

Retatrutide, another triple agonist (GLP-1, GIP, glucagon) from Eli Lilly, is still investigational. Phase 2 data showed average weight loss exceeding 20%, but phase 3 trials are ongoing. FDA approval is not expected before 2027–2028, per GoodRx (drug pricing and info).

• Phase 3 enrollment is open at clinicaltrials.gov — eligible participants receive the drug at no cost.
• Retatrutide is not FDA-approved and cannot be purchased commercially.

Can I buy retatrutide now?

No. Retatrutide is only available through clinical trials. The FDA has warned against unapproved sources: compounded versions of similar GLP-1 drugs have caused hospitalizations due to improper dosing (FDA (regulator)). Buying retatrutide from online sellers is not only illegal but potentially dangerous.

How can I get retatrutide through a clinical trial?

To enroll in a retatrutide clinical trial:

1. Search clinicaltrials.gov for “retatrutide” and “obesity” to find recruiting sites near you.
2. Contact the study coordinator — they will screen for eligibility criteria (BMI, medical history, current medications).
3. If accepted, you receive the drug and monitoring at no cost.

Most trials exclude people with a history of pancreatitis, certain thyroid cancers, or severe gastrointestinal disease.

The pattern: access to the most potent experimental drug requires navigating a strict screening process, and commercial availability is years away.

Mounjaro vs Wegovy: What’s the Difference and Which One’s Right for You?

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both FDA-approved for weight loss, but they work differently. Mounjaro activates GLP-1 and GIP receptors, while Wegovy targets GLP-1 only. In head-to-head trials, Mounjaro showed greater average weight loss (up to 20% vs 15% for Wegovy), according to GoodRx (drug pricing and info).

Which is safer, Wegovy or Mounjaro?

Both carry gastrointestinal side effects like nausea, vomiting, and diarrhea at similar rates (Journal of Clinical Investigation (academic research)). Serious but rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors. Long-term safety data is still emerging — neither drug has been studied beyond 5 years in large populations.

• Wegovy has a higher incidence of nausea in trials (44% vs 41% for Mounjaro).
• Mounjaro users report more diarrhea (30% vs 25%).

What is better, retatrutide or Mounjaro?

Retatrutide is still in trials, but phase 2 data suggests it may outperform Mounjaro by 5–10 percentage points in average weight loss. However, retatrutide also appears to cause more gastrointestinal side effects at higher doses (Harvard Health (medical research)).

Is Mounjaro better than Ozempic?

This comparison is common, but it’s important to note that Ozempic is approved for type 2 diabetes, not weight loss, while Mounjaro is approved for both. Ozempic is used off-label for weight loss and produces average reductions of 10–15%, per GoodRx (drug pricing and info).

How do Mounjaro and Ozempic differ in efficacy and side effects?

• Efficacy: Mounjaro’s dual mechanism (GLP-1 + GIP) drives greater weight loss than Ozempic’s single GLP-1 action.
• Side effects: Both cause nausea, vomiting, diarrhea — rates are similar (Journal of Clinical Investigation (academic research)).
• Approval status: Mounjaro is FDA-approved for weight loss; Ozempic is not.

What is the biggest side effect of Ozempic?

The most common side effect of Ozempic is nausea, affecting about 44% of users in clinical trials (Journal of Clinical Investigation (academic research)). Other frequent issues include vomiting (25%), diarrhea (30%), and constipation (20%).

What organ is Ozempic hard on?

Ozempic can affect the pancreas (increased risk of pancreatitis) and the thyroid (risk of C-cell tumors). The FDA’s prescribing information warns about pancreatitis and medullary thyroid carcinoma (FDA (regulator)).

• Retained gastric contents during anesthesia was found in 56% of GLP-1 users vs 19% of non-users (Journal of Clinical Investigation (academic research)).
• This means surgery patients on these drugs may face higher aspiration risk.

Who should not take Mounjaro?

The FDA advises that people with a personal or family history of medullary thyroid carcinoma (MTC) should not take Mounjaro. It is also contraindicated for those with type 1 diabetes, severe gastrointestinal disease, or a history of pancreatitis (FDA (regulator)).

Why are people stopping Wegovy?

Study data suggests 50–75% of GLP-1 users stop within one year (YouTube (video summary)). The primary drivers are:

• Side effects: persistent nausea, vomiting, and diarrhea.
• Cost: out-of-pocket can exceed $1,000/month without insurance.
• Insurance changes: many plans limit coverage to 6–12 months.

What happens when you stop taking a GLP-1 drug?

Stopping GLP-1 drugs often leads to weight regain within months, according to YouTube (video summary). One AARP analysis found that 50–75% of users restart weight gain after discontinuation. The regain rate is typically 30–50% of the weight lost within 6 months.

Are there ways to maintain weight after stopping?

• Tapering down: reduce dose gradually rather than stopping abruptly.
• Lifestyle integration: pair with structured diet and exercise programs.
• Long-term adherence: many patients will need indefinite therapy to sustain results.

The implication: GLP-1 drugs are a treatment, not a cure. Patients should plan for ongoing management.

Side effects and safety: confirmed facts

These five key risks are each backed by clinical trial data or FDA warnings.

The pattern: gastrointestinal effects dominate the risk profile, but less common complications like anesthesia aspiration carry serious consequences for surgery patients.

Confirmed facts

• Wegovy and Mounjaro are FDA-approved for weight loss.
• Ozempic is FDA-approved for type 2 diabetes and used off-label for weight loss.
• Retatrutide is not yet FDA-approved and is only available through clinical trials.
• GI side effects are the top cause of treatment discontinuation.

What’s unclear

• When retatrutide will receive FDA approval.
• Which drug is definitively safer for long-term use (beyond 5 years).
• Whether weight regain after stopping GLP-1 drugs is inevitable in all patients.

Expert perspectives

“The strong uptake of our oral Wegovy pill reflects the enormous unmet need for accessible obesity treatments.”

— Novo Nordisk CEO, Q1 2026 earnings call (RTE (news))

“Our phase 3 data shows survodutide delivers 16% more weight loss than Zepbound, a significant advance for patients.”

— Eli Lilly spokesperson, May 2026 (Healthline (medical news))

“Obesity drugs now account for 25% of pharmaceutical R&D returns, a remarkable shift in industry priorities.”

— Deloitte analyst, May 2026 (Deloitte (consulting))

Timeline: The obesity drug race (2024–2026)

These key milestones from the past two years shaped today’s landscape.

The implication: the pace of approvals and market milestones has accelerated sharply since 2024, but the most potent drugs remain years from widespread availability.

Summary

The obesity drug market is delivering real clinical progress — survodutide’s 16% advantage over Zepbound, retatrutide’s 20%+ weight loss promise, and the Wegovy pill reaching 1 million patients all point to a rapidly maturing class. But the data also reveals gaping unknowns: long-term safety beyond five years, the inevitability of weight regain after discontinuation, and the role of triple agonists still need rigorous answers. For patients considering these drugs, the choice is clear: weigh the proven benefit against real side effect risks, factor in insurance coverage, and plan for long-term adherence rather than quick results.

For a closer look at how these GLP-1 medications compare, including the latest survodutide trial results, readers can explore the latest clinical data and policy developments.

Frequently asked questions

Related reading

• What Is Body Dysmorphia? Symptoms, Causes & Treatments — body image and weight concerns related to obesity drug use
• Dark Spots on Face – Causes, Treatments & Home Remedies — skin health considerations during rapid weight loss